P2.04-24 Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1248
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn228 - Real-World Use of Pembrolizumab and Nivolumab From Clinical Trials to Market Launch: What Can Be Learned?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Are Results From Clinical Trials Reliable?

The Lancet Oncology
Oncology
2019English

GetReal: From Efficacy in Clinical Trials to Relative Effectiveness in the Real World

Research Synthesis Methods
Education
2016English

Effectiveness and Safety of Nivolumab in the Treatment of Lung Cancer Patients in France: Preliminary Results From the Real-World EVIDENS Study

OncoImmunology
OncologyAllergyImmunology
2020English

Are These Data Real? Statistical Methods for the Detection of Data Fabrication in Clinical Trials

BMJ
2005English

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results From a Real‐World Population

Oncologist
Cancer ResearchMedicineOncology
2019English

P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Expert Clinical Management of Autoimmune Hepatitis in the Real World

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2016English

The Inclusion of Real World Evidence in Clinical Development Planning

Trials
MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy